The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient-reported outcomes for hidradenitis suppurativa
The HSSID appropriately assesses the symptoms and impacts of HS in adults. HSSID items demonstrated generally robust psychometric properties.
Authors
- Randall H. Bender (ORCID: https://orcid.org/0000-0001-5565-4712)
- Jessica Marvel (ORCID: https://orcid.org/0000-0002-0757-5865)
- Santiago G. Moreno (ORCID: https://orcid.org/0000-0002-6341-7546)
- Lorenz Uhlmann (ORCID: https://orcid.org/0000-0001-8668-069X)
- Susan Martin (ORCID: https://orcid.org/0000-0002-9594-5036)
- John R Ingram (ORCID: https://orcid.org/0000-0002-5257-1142)
- Lori McLeod (ORCID: https://orcid.org/0000-0002-7837-8033)
- Angela Llobet Martinez
- Alexa B. Kimball (ORCID: https://orcid.org/0000-0001-9405-0479)
- Falk G. Bechara (ORCID: https://orcid.org/0000-0003-0418-521X)
- Magdalena B. Wozniak (ORCID: https://orcid.org/0000-0002-4411-2747)
- Anna Passera
- Shoba Ravichandran
Institutions
- Novartis (Switzerland) (CH)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- University Hospitals of the Ruhr-University of Bochum (DE)
- Novartis (United States) (US)
- RTI Health Solutions (US)
- Novartis (Ireland) (IE)
- Hidradenitis Suppurativa Foundation (US)
- Tris Pharma (United States) (US)
- Institute of Infection and Immunity (CA)
- Cardiff University (GB)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1093/bjd/ljaf307
- Citations
- 1
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.00
Funders
- Novartis Pharma
- Novartis Pharmaceuticals UK Limited